↓ Skip to main content

Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study

Overview of attention for article published in Arthritis Research & Therapy, March 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study
Published in
Arthritis Research & Therapy, March 2017
DOI 10.1186/s13075-017-1222-3
Pubmed ID
Authors

Peter C. Grayson, Yusuf Yazici, Melissa Merideth, H. Nida Sen, Michael Davis, Elaine Novakovich, Elizabeth Joyal, Raphaela Goldbach-Mansky, Cailin H. Sibley

Abstract

The effect of IL-1 blocking therapy on mucocutaneous manifestations of Behçet's disease is incompletely understood. Six patients with Behçet's disease and ongoing oral/genital ulcers for ≥1 month were enrolled into an adaptive, two-phase clinical trial and included in the analysis. Study duration was 6 months with extension up to 16 months. All were treated non-blinded with anakinra 100 mg subcutaneous daily with the option to escalate the dose to 200 mg in partial responders after 1 month and 300 mg after 6 months. Patients recorded the number and severity of ulcers in daily diaries. The primary outcome was remission defined as no ulcers on physical exam for two consecutive monthly visits between months 3 and 6. Secondary outcomes included the number and severity of patient-reported ulcers, patient/physician global scores, and standardized disease activity scores. Two of six patients achieved the primary outcome. Five of six patients had improvement in the number and severity of ulcers. Non-statistically significant improvements were seen in secondary outcomes. Over the entire study, patients reported ≥1 oral and ≥1 genital ulcer on 665 (66%) and 139 (14%) days, respectively. On anakinra 200 mg vs 100 mg, patients reported fewer days with oral ulcers (65% vs 74% of days, p = 0.01) and genital ulcers (10% vs 22% of days, p < 0.001) and milder oral ulcer severity (p < 0.001). Increase of anakinra to 300 mg did not result in further improvements. Adverse events were notable for mild infections. Anakinra at an optimal dose of 200 mg daily had an acceptable safety profile and was partially effective in the treatment of resistant oral and genital ulcers in Behçet's disease. Clinicaltrials.gov. NCT01441076 . Registered on 24 September 2011.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Other 9 21%
Student > Master 6 14%
Student > Bachelor 4 10%
Student > Postgraduate 4 10%
Researcher 3 7%
Other 7 17%
Unknown 9 21%
Readers by discipline Count As %
Medicine and Dentistry 21 50%
Neuroscience 2 5%
Social Sciences 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Computer Science 1 2%
Other 3 7%
Unknown 12 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2017.
All research outputs
#1,724,155
of 11,622,318 outputs
Outputs from Arthritis Research & Therapy
#376
of 1,602 outputs
Outputs of similar age
#59,478
of 262,877 outputs
Outputs of similar age from Arthritis Research & Therapy
#5
of 13 outputs
Altmetric has tracked 11,622,318 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,602 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,877 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.